Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period, driven by approximately $11 million in net sales of TONMYA, its recently approved fibromyalgia treatment. The company also announced that TONMYA recorded 12,592 total prescriptions during the quarter, a 100% sequential increase, with new patient prescriptions up 36% and refills soaring 207%. This performance underscores the rapid adoption of the first new treatment for fibromyalgia in over 15 years.
TONMYA's market access has expanded significantly, with current coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. This coverage is expected to reach approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. The expansion in coverage is likely to enhance patient access and drive further prescription growth, solidifying TONMYA's position in the fibromyalgia market.
Beyond commercial success, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder (MDD). This study could open new indications for the drug, addressing a significant unmet medical need in mental health. Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. This initiative targets a growing public health concern, as Lyme disease cases continue to rise in many regions.
The company ended the quarter with approximately $176.2 million in cash and cash equivalents. Management stated that these resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This financial runway provides stability for ongoing research and development activities.
The robust revenue and pipeline progress highlight Tonix's transformation into a commercial-stage biotechnology company. The strong sales of TONMYA and the promising pipeline could have significant implications for patients suffering from fibromyalgia, MDD, and Lyme disease. For the industry, this demonstrates the potential of repurposing existing drugs for new indications and the importance of strategic market access in driving commercial success.
Investors and stakeholders can find more details in the full press release at https://nnw.fm/6Yytj. For ongoing updates on Tonix Pharmaceuticals, visit the company's newsroom at https://nnw.fm/TNXP.
